Mucosal Interleukin-10 Depletion in Steroid-refractory Crohn's Disease Patients

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2022 Sep 28

PMID 36169258

Authors

Anna Carrasco

Eva Tristan

Fernando Fernandez-Banares

Albert Martin-Cardona

Montserrat Aceituno

Yamile Zabana

Lourdes Fluvia

Jose Maria Hernandez

Violeta Loren

Josep Manye

Antonio Salas

Xavier Andujar

Carme Loras

Maria Esteve

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies suggested that Interleukin-10 (IL-10) depletion in Crohn's disease (CD) could predict outcome.

Aim: To determine IL-10 in blood and at different intestinal locations in patients with active CD and to assess its potential prognostic capacity to identify aggressive CD.

Methods: Twenty-three patients with CD were included. Ulcerative colitis (UC), infectious colitis and healthy individuals acted as controls. Serum and mucosal samples were taken at baseline and 1 month after steroid initiation in CD patients. Patients were classified according to steroid response. Control samples were obtained from different intestinal locations. IL-10 expression was measured with real-time polymerase chain reaction, immunofluorescence (intestine) and ELISA (serum, biopsy cultures' supernatants and tissue homogenates).

Results: CD and UC showed an increase in IL-10 messenger RNA (mRNA) versus controls (p < .0001) in mucosa, whereas IL-10 protein secretion was increased in all types of intestinal inflammation (p < .001). No differences in IL-10 mRNA were found in CD at baseline regarding steroid response, but levels decreased in non-responders versus responders (p = .027) and were restored with rescue therapy. Serum IL-10 was increased in steroid-refractory CD at baseline and after treatment.

Conclusions: Abnormal IL-10 levels in refractory patients in both mucosa and blood have physiopathological relevance and may have potential clinical applications.

Citing Articles

Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients.

Carrasco A, Tristan E, Fernandez-Banares F, Martin-Cardona A, Aceituno M, Zabana Y Immun Inflamm Dis. 2022; 10(10):e710.

PMID: 36169258 PMC: 9514060. DOI: 10.1002/iid3.710.

References

Fowler E, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D . TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet. 2005; 42(6):523-8. PMC: 1736076. DOI: 10.1136/jmg.2004.027425. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

Mullin G, Maycon Z, Braun-Elwert L, Cerchia R, James S, Katz S . Inflammatory bowel disease mucosal biopsies have specialized lymphokine mRNA profiles. Inflamm Bowel Dis. 2013; 2(1):16-26. View

Daperno M, DHaens G, Van Assche G, Baert F, Bulois P, Maunoury V . Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004; 60(4):505-12. DOI: 10.1016/s0016-5107(04)01878-4. View

Ye B, McGovern D . Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. Expert Rev Clin Immunol. 2016; 12(10):1091-107. PMC: 5083126. DOI: 10.1080/1744666X.2016.1184972. View

Santaolalla R, Mane J, Pedrosa E, Loren V, Fernandez-Banares F, Mallolas J . Apoptosis resistance of mucosal lymphocytes and IL-10 deficiency in patients with steroid-refractory Crohn's disease. Inflamm Bowel Dis. 2011; 17(7):1490-500. DOI: 10.1002/ibd.21507. View

de Souza H, Fiocchi C . Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2015; 13(1):13-27. DOI: 10.1038/nrgastro.2015.186. View

Oemrawsingh R, Lenderink T, Akkerhuis K, Heeschen C, Baldus S, Fichtlscherer S . Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart. 2011; 97(13):1061-6. DOI: 10.1136/hrt.2010.197392. View

Carrasco A, Tristan E, Fernandez-Banares F, Martin-Cardona A, Aceituno M, Zabana Y . Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients. Immun Inflamm Dis. 2022; 10(10):e710. PMC: 9514060. DOI: 10.1002/iid3.710. View

10.

DHaens G, Sandborn W, Feagan B, Geboes K, Hanauer S, Irvine E . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763-86. DOI: 10.1053/j.gastro.2006.12.038. View

11.

Gunaltay S, Nyhlin N, Kumawat A, Tysk C, Bohr J, Hultgren O . Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis. World J Gastroenterol. 2014; 20(34):12249-59. PMC: 4161810. DOI: 10.3748/wjg.v20.i34.12249. View

12.

Mannon P, Leon F, Fuss I, Walter B, Begnami M, Quezado M . Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells. Clin Exp Immunol. 2008; 155(3):447-56. PMC: 2669521. DOI: 10.1111/j.1365-2249.2008.03799.x. View

13.

Dussault A, Pouliot M . Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol Proced Online. 2006; 8:1-10. PMC: 1352391. DOI: 10.1251/bpo114. View

14.

Mowat A, Agace W . Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014; 14(10):667-85. DOI: 10.1038/nri3738. View

15.

Welsh P, Murray H, Ford I, Trompet S, de Craen A, Jukema J . Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol. 2011; 31(10):2338-44. DOI: 10.1161/ATVBAHA.111.231795. View

16.

Correa I, Veny M, Esteller M, Pique J, Yague J, Panes J . Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol. 2009; 85(5):896-903. DOI: 10.1189/jlb.1108698. View

17.

Meresse B, Rutgeerts P, Malchow H, Dubucquoi S, Dessaint J, Cohard M . Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut. 2002; 50(1):25-8. PMC: 1773067. DOI: 10.1136/gut.50.1.25. View

18.

Westendorp R, Langermans J, Huizinga T, Elouali A, Verweij C, Boomsma D . Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997; 349(9046):170-3. DOI: 10.1016/s0140-6736(96)06413-6. View

19.

Quiros M, Nishio H, Neumann P, Siuda D, Brazil J, Azcutia V . Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. J Clin Invest. 2017; 127(9):3510-3520. PMC: 5669557. DOI: 10.1172/JCI90229. View

20.

Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. View